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Abstract Preclinical research into radionuclide therapies based
on radiation dosimetry will enable the use of any LET-
equivalent radionuclide. Radiation dose and dose rate have
significant influence on dose effects in the tumour depending on
its radiation sensitivity, possibilities for repair of sublethal
damage, and repopulation during or after the therapy. Models
for radiation response of preclinical tumour models after peptide
receptor radionuclide therapy based on the linear quadratic
model are presented. The accuracy of the radiation dose is very
important for observation of dose-effects. Uncertainties in the
radiation dose estimation arise from incomplete assay of the
kinetics, low accuracy in volume measurements and absorbed
dose S-values for stylized models instead of the actual animal
geometry. Normal dose uncertainties in the order of 20% might
easily make the difference between seeing a dose-effect or
missing it altogether. This is true for the theoretical case of a
homogeneous tumour type behaving in vivo in the same way as
its cells do in vitro. Heterogeneity of tumours induces variations
in clonogenic cell density, radiation sensitivity, repopulation
capacity and repair kinetics. The influence of these aspects are
analysed within the linear quadratic model for tumour response
to radionuclide therapy. Preclinical tumour models tend to be
less heterogenic than the clinical conditions they should
represent. The results of various preclinical radionuclide therapy
experiments for peptide receptor radionuclide therapy are
comparedtotheoutcomeoftheoreticalmodelsandtheinfluence
of increased heterogeneity is analysed when the results of
preclinical research is transferred to the clinic. When the
radiation dose and radiobiology of the tumour response is
known well enough it may be possible to leave the current
phenomenological approach in preclinical radionuclide therapy
and start basing these experiments on radiation dose. Then the
use of a gamma ray-emitting radionuclides for a chemically
comparable beta-particle-emitting paired isotope for therapy
evaluation would be feasible.
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Introduction
Preclinical research into radionuclide therapy has only
recently shifted gear when specific animal dose models were
introduced and evaluation of dosimetry and dose-effect
models are increasingly being performed and consequently
dose-effect relations are now being investigated [1–4]. The
research into dose-effect models for radionuclide therapies is
mainly aimed at reducing radiation toxicity in normal organs
which show physiological uptake of the radiolabelled
compound. The efficacy of radionuclide therapies is mainly
studied at a phenomenological level: a practical amount of
radioactivity is used and the reduction in tumour size
observed, while keeping the radiation toxicity manageable.
The therapeutic effect of radionuclide therapy has been
tested inmice and ratsinvarious settings[5]. The response of
tumours has scarcely been studied in relation to the radiation
dose given, and is usually reported in relation to the activity
administered. When radiation doses are reported at all it is
usually for a single type of administration, making a
dynamic interpretation of the dose–effect relationship by,
for example, fractionation difficult to interpret. Tumour
growth suppression of 4–5 weeks has been reported by Behr
et al. after administration of 8–10 Gy by
90Y-labelled CEA
antibody fragments in xenografted mice [6]. Higher tumour
doses shifted the suppression further, but renal and haemato-
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Different dosimetry models were tested ranging from spheres
with just self-doses with activity inside the tumour or organ,
to a cylindrical mouse model [4] with cross-organ dose
contributions, to a realistic mouse model based on ultrasound
imaging geometry. The choice of dose model influenced, for
example, the kidney dose by more than 50% [6].
Peptidereceptorradionuclidetherapyisbasedondose-driven
preclinical experiments. Rats with subcutaneously implanted
somatostatin receptor-positive CA20948 tumours were injected
with
90Y-DOTA,Tyr
3-octreotide [7]o rw i t h
177Lu-DOTA,Tyr
3-
octreotate [8]. A difference in tumour killing efficacy was
observed between the responses of tumours of different size.
An activity of 370 MBq
90Y-DOTA,Tyr
3-octreotide led to
complete cure only in tumours with a surface area of 3–9c m
2,
whereas this activity led to only a partial response and
prolongation of survival times in smaller tumours. With
177Lu-DOTA,Tyr
3-octreotate, on the other hand, two doses of
277.5 MBq led to a complete response in small tumours with a
surface area less than 1 cm
2. Dosimetry was reported for both
situations: 370 MBq
90Y-DOTA-octreotide yielded a dose
ranging from 48 Gy (1-g tumour) to 60 Gy (10-g tumour) and
2×277.5 MBq
177Lu-DOTA,Tyr
3-octreotate yielded a dose of
58 Gy to a tumour from 1 to 10 g independent of size. The
dose model used was a spherical tumour without a cross-fire
dose from other organs, which is acceptable with the shorter-
ranged beta-particles from
177Lu and the larger rat dimensions,
but is prone to systematic errors for the longer-ranged β-rays
from
90Y[ 4].
Dose-effect relations for tumour control
It is also possible to use
111In-labelled peptides to study dose-
effects both in tumours [9, 10]a sw e l la si nn o r m a lt i s s u e[ 11].
The conversion and Auger electrons in the spectrum of
111In
are capable of creating doses to the tumours in the curable
range but also doses to the kidneys near the threshold for renal
damage. It has been shown that the survival of rats with
subcutaneously implanted CA20948 tumours with a size less
than 1 cm
2 could be prolonged and the prolongation time was
activity-dependent. In larger tumours no prolongation of
survival was seen. Radiation doses to the tumours of about
10 Gy were achieved, but unfortunately no specific dosimetry
was performed, so this dose forms a crude estimate. In another
study in rats, the doubling time of implanted CA20948
tumours was found to be 8±1 days [12].
Apparently tumour doses larger than 10 Gy are needed for
cure of rat CA20948 tumours. This dose is much lower than the
therapeutic doses needed clinically as shown by Pauwels et al.
[13]. Tumour shrinkage after
90Y-DOTA-octreotide therapy in
patients with neuroendocrine tumours shows only a clear
correlation with radiation doses above 120–150 Gy. It is
therefore of great importance to set up preclinical radiation
dosimetry experiments that clarify the relationships between
radiation dose, response and tumour cell properties. Radiation
sensitivity, growth pattern and heterogeneity of tumour
(uptake) are important cell properties to be investigated, as
they influence tumour control [14]. The radiation sensitivity,
tumour growth and heterogeneity of neuroendocrine tumours
in humans are different from the preclinical therapy model
[15], but when the conditions for each setting are known
predictive preclinical therapy research can be performed with
any radionuclide emitting low-LET radiation.
Relation tumour size and beta-particle range
In ground-breaking studies by O’Donoghue et al. [16]a n d
Nahum [17], it was shown that dose, particle range and tumour
size are important factors that define the probability of cure
with radionuclides. Important factors in the response and
growth of tumour cells are the radiosensitivity α and the
tumour doubling time TD. The surviving numbers of clono-
genic cells after irradiation follow the linear quadratic (LQ)
model. The quadratic term is neglected as this term expresses
the component of repairable damage to cells which is
negligible with low dose-rate exposure [18], and hence a
linear exponential relationship with the dose is given by:
S ¼ exp  aED ðÞ ; with :E ¼ 1  
g
aR0 1   ln
g
aR0






where the dose D is given by a monoexponentially decaying
dose rate R with (effective) decay constant l (=ln(2)/T1/2)
and initial dose rate R0, according to R(t)=R0exp(−lt). The
effective tumour repopulation constant + (=ln(2)/TD)i nt h e
dose wasted-by-proliferation term E only works when the
dose rate remains larger than +/α. After in-vitro
irradiation of CA20948 cells with
131I an almost linear
cell survival dose–effect curve was found, whereas
following exposure to X-rays survival showed the typical
LQ model curvature (Fig. 1)[ 19]. The parameters of the
LQ model curve fitted to these data yielded: α=0.3/Gy
(X-rays) to 0.35/Gy (
131I). The difference between the
found α-values was not significant, but the difference in
curvature was. On exposure to X-rays the curvature could
be expressed by an α/β ratio of 8.3 Gy, and exposure to
131Ib ya nα/β ratio of 102 Gy. This straightening out of
the LQ curve can be explained by almost complete repair
of the sublethal damage, but could also be an indication of
the LQ(L) model, as used to explain responses to
hypofractionated radiotherapy [20]. Contrary to the gen-
eral idea, large α/β ratios can also occur in tumours that
repopulate quickly [21].
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Repopulation of clonogenic tumour cells escaping cell kill
during and after radiotherapy is of great concern in
protracted therapy schemes, such as low dose-rate brachy-
therapy and possibly also radionuclide therapy. The
hypothesis that tumours always have high a α/β ratio has
been found not to hold with all types of cancer, for that
reason Eq. 1 can be adjusted to include the quadratic term
[22, 23]:
S ¼ exp  aD   GbD2 þ gT
  
; ð2Þ
where G is the dose protraction factor accounting for sublethal
damage repair during radiation exposure, α and β represent the
linear and quadratic intrinsic radiosensitivity, respectively, and
+ is the tumour repopulation rate as defined in Eq. 1.F o rt h e
monoexponential decaying dose rate, the treatment time T is
defined as the time during which the dose rate remains larger
than +/α and hence the number of cells killed by radiation
outweighs the number of cells from tumour growth:
D¼
R0
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where μ is the rate of repair of sublethal damage in the tumour
cells (=ln(2)/Trep) and the median tumour repair half-life Trep is
60 min [24]. The repair half-life for an intermediate risk group
of prostate cancer was derived from clinical data at Trep=
16 min [23]. No study has been performed on the repair half-
life of neuroendocrine tumours or of CA20948 tumours.
The probability of local control of a tumour treated by
radiotherapy is thought to depend on the number of surviving
tumour cells according to Poisson statistics. The tumour control
probability (TCP) is therefore defined as a function of S as:
TCP ¼ exp  KS ðÞ ð 4Þ
where K standsforthe initialnumberofclonogenic tumourcells
and depends strongly on its risk level. O’Donoghue assumed for
a1 - gt u m o u raK of 3×10
7 clonogenic cells [16]. This
magnitude of clonogen density would correspond to a high risk
(aggressive) type of tumour [24, 25]. An intermediate risk
group of prostate cancers with a clonogen cell density of 3 ×
10
6 cells/g was chosen in the TCP model by Wang and Li
[23], and this choice was followed in this study, as well as
higher cell densities. Tumour repopulation after irradiation is
delayed by a lag or kick-off time Tk, which could be as long as
40 days for CA20498 [12]. Prostate cancer (PC-3) tumour-
bearing mice in response to a low dose of 14 Gy of the
177Lu-
labelled bombesin analogue AMBA showed a progression-free
survival of 37 days [26]. Both the tumour growth curves for
PC-3 after treatment with
177Lu AMBA and for CA20948 after
treatment with
111In-DOTA-octreotate [9]s h o wal a gt i m eo f
approximately 21 days. This lag time was incorporated into the
tumour cell survival by replacing T by T−Tk in Eq. 2.
Application of LQ model in peptide receptor
radionuclide therapy
The consequence of the radiation sensitivity of α=0.35/Gy for
cell survival as a function of dose without cell growth is
shown in Fig. 2. When the dose is calculated with an error of
10%, which would be outstanding in radionuclide dosimetry,
the 95% confidence interval for cell survival after receiving a
dose of 50 Gy would range between 1.24 and 0.005 cells for a
1-g tumour with 3×10
6 tumour cells. This represents a
difference between no response and cure, as expressed with
the TCP, which ranges between 1% and 98%. This huge
amplification of the dose shows the necessity for obtaining
high accuracy in dosimetry measurements. To obtain this, the
accuracay of all dose aspects should be improved: the kinetics
of the radiolabelled compound, determination of tumour
volume and calculation of the radiation transport. The cell
survival curve is linear exponential with one-log of cell kill
after D0=2.9 Gy. To obtain certain cures the dose should be
>61 Gy for a 0.01-g tumour, >78 Gy for a 1-g tumour and
>94 Gy for a 100-g tumour. When considering the dose effect
of peptide receptor radionuclide therapy that was observed in
rats, the uptake kinetics also need to be incorporated. The
kinetic data for
177Lu-DOTA-octreotate [8] was used with an
uptake in the tumour of 0.96±0.15%/g and uptake half-life of
14±19 min and a clearance half-life of 34±6 h.
Fig. 1 Clonogenic survival curve for CA20948 using two methods:
(1) external-beam therapy (dashed line), and (2) radionuclide therapy
(solid line). The data presented are the means ± standard deviation
from at least three independent experiments (taken from reference [15]
with permission of the publisher)
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cell survival, as shown in Fig. 3, is striking, especially since for
177Lu the maximum activity of 555 MBq was not analysed,
whereas for the other two the maximum activity was used.
Only
177Lu is capable of creating a high enough cell kill in
tumours of all sizes, although its effect is reduced in the larger
tumours. The low-energy electron spectrum from
111In
produces curable conditions in the smallest tumours, but its
effect diminishes in tumours of intermediate size. The increase
in cell kill in the larger tumours is a result of its gamma rays.
As expected, only larger tumours respond well to
90Y. The
differences in dose-response for the radionuclides can be
explained by the differences in dose (in a 1-g tumour:
90Y
46 Gy,
111In 3×14 Gy, and
177Lu 64 Gy). The fractionation of
111In helps to shift regrowth to later time-points.
The robustness of the dose-response models can be tested by
varyingtheirparameters.Reducingthetumourcellrepopulation
lag time to 10 days has little effect (Fig. 4; only the duration of
the cure is reduced), but at lag times less than 5 days the TCP
following irradiation with
111In is eliminated as a result of
repopulationofthetumourduringtheintervalsbetweenthetherapy
cycles with which
111In is given. As this repopulation has not
been observed with a lag time longer than 10 days, it was set at
14 days. Raising the clonogenic cell density by a factor of 10, to
3×10
7, will considerably reduce the TCP with
90Ya n d
111In
(Fig. 5). For example, raising the clonogenic cell density by a
factor of 10 in a 10-g tumour will reduce the TCP of
90Yf r o m
88% to 28%, but as cures were observed in the larger tumours a
clonogen density of 3×10
6 cells/g seems to be a reasonable
estimate. Remarkably,
177Lu is able to cure small and medium-
size tumours over the whole range of clonogen density. Varying
the tumour repopulation time TD has no effect on the TCP, but
only on the time to regrowth. The linear radiation sensitivity
factor α has a direct influence on the TCP. With
177Lu it is
possible to cure a 1-g tumour with radiation sensitivities above
0.28/Gy, whereas with
90Y this threshold is 0.38/Gy (Fig. 6a). In
smaller tumours, the threshold for
177Lu is even lower (0.22/
Gy). Decreasing the α/β ratio from 103 Gy to 10 Gy has no
influence on the TCP of
177Lu, but slightly increases the TCP of
90Y, and also increases that of
111In (Fig. 6b). Increasing the
r e p a i rh a l f - l i f ef r o m1 6m i nt o2ha f f e c t si np a r t i c u l a rt h eT C P
of
90Y: in a 1-g tumour the TCP increases from 81% to 88%.
Increasing the repair half-life has little effect on either
177Lu or
111In. This is because of their lower dose rates which are a
consequence of the longer half-life of
177Lu and the fractionation
of the dose of
111In. With lower α/β ratios the effect of
increasing the repair half-life Tμ would be greater.
As injected activity is the most easily measured quantity,
TCP as a function of injected activity, as shown in Fig. 7,
illustrates much of the preclinical findings for radionuclide
therapy efficacy. With
90Y cure of tumours less than 1 g in
weight is only possible at high activities, which are impossible
to administer in one shot. At a feasible dose of 370 MBq,
90Y
can cure tumours from 1 to 100 g in weight. Three shots of
111In can cure tumours of the lowest weight considered
(0.01 g), as well as tumours above 1 g. Only
177Lu is able to
cure tumours over the whole weight range considered.
The radiation doses to the tumour and organs are not
always homogeneously distributed. With a gaussian
distributed variation (with standard deviation sigma) in
the dose over the tumour the homogeneous TCPhom can
Fig. 2 Theoretical tumour cell survival curves for CA20948 tumour
cells (top graph) and local tumour control probability (TCP, bottom
graph) as a function of dose for five tumour weights. The arrows show
the 95% confidence intervals with 10% uncertainty in a dose of 50 Gy
in a 1-g tumour producing a TCP of 74% (95%CI 1–98%). Radiation
sensitivity α=0.25/Gy, clonogenic cell density 3×10
6 cells/g, and
tumour cell doubling time TD=4 days
Fig. 3 Theoretical survival curves of clonogenic cells and consequent
TCP in 0.01-g, 0.1-g, 1-g and 10-g tumours after irradiation with
370 MBq
90Y, 370 MBq
111In three times, and 277.5 MBq
177Lu, all
according to the tumour uptake kinetics observed with
177Lu DOTA-
octreotate in rats bearing CA20948 tumours
b








TCPhom $ ðÞ d$. The resulting graphs are
shown in Fig. 8. A variance in the radiation dose to the
tumour of 50% reduces tumour control with the high-dose
administrations (555 and 277.5 MBq) 100 days after
administration from 100% to 60–90%, whereas low doses
only show therapeutic effects when the variance in the dose
is high enough. The equivalent uniform dose is the
uniformly distributed dose, or biologically effective dose,
that produces an equivalent cell kill to the actual non-
uniformly distributed dose [27].
Discussion and conclusion
It is possible to use dosimetry to guide preclinical therapy
studies. Dose–effect curves for tumour cell kill should be
obtained with the highest possible accuracy, as the steepness of
the curve amplifies the uncertainty of the outcome. As
111In is
superior for imaging and offers the possibility of good
quantitation, this radionuclide could be used successfully to
study dose-effects of radionuclide therapy as a model for other
low-LET radiation emitters. The Auger electron part of its
spectrum may form a high-LET exposure, but only when
incorporated into the cell nucleus. Most peptides remain on the
cell membrane or in the cytoplasm and do not penetrate into
the nucleus. The problem with using
111In for therapeutic doses
is its limited specific activity disabling high activity labelling of
low peptide amounts. This problem can be circumvented by
administering multiple doses.
The fundamental radiation sensitivity properties of the
tumour models in preclinical therapy should be determined.
Studies should identify the lag time in repopulation and
tumour doubling time after radionuclide exposure. The
Fig. 4 Theoretical TCP for a 1-g tumour as a function of tumour cell




Fig. 5 Theoretical TCP of CA208948 tumours in rats as a function of
clonogenic cell density K for four tumour weights (0.01, 1, 10 and
100 g) and three radionuclides
S24 Eur J Nucl Med Mol Imaging (2011) 38 (Suppl 1):S19–S27repopulation lag time after giving a radiation dose may
obscure the effect of variations in tumour repopulation,
which can cause therapy resistance [29]. Radiation sensi-
tivity parameters α and possibly the curvature α/β should
be determined, with the appropriate repair half-life. Clono-
genic cell density plays an important role in the tumour
cure models, but implanted tumours are most probably
Fig. 6 Theoretical TCP of 1-g CA208948 tumours in rats as a
function of radiation sensitivity parameters according to the LQ
model: linear coefficient α, curvature α/β and repair half-life of
sublethal damage Tμ for three radionuclides
Fig. 7 Theoretical TCP as a function of administered activity, with 3×10
6
clonogenic cells/g, α=0.35/Gy, α/β=103 Gy, Tμ=16 min, Tk=14 days,
tumour uptake 0.96±0.15%/g and clearance half-life of 34±6 h
Eur J Nucl Med Mol Imaging (2011) 38 (Suppl 1):S19–S27 S25much more aggressive than neuroendocrine tumours in the
clinic. This might induce a conceptual error in preclinical
research into these tumours, as aggressive tumours tend to
show more direct effects than those growing more slowly.
This might indicate beneficial effects of fractionation in
reducing toxicity without reducing therapeutic efficacy. In
reality neuroendocrine tumours may behave as a late-
responding tissue, where fractionation will reduce toxicity
but also therapeutic efficacy [23].
Variation in the dose over the tumour [27], and also
heterogeneity of the tumour itself, might prevent the
observation of clear dose-effects [14, 28]. It is, however,
very difficult to image heterogeneity in the activity
distribution over the tumour, unless ex-vivo autoradiogra-
phy or a high-resolution (pinhole) camera can be used.
Heterogeneity in tumour cell kinetics as a result of variation
in clonogenic cell density [14], cell growth [29] or radiation
sensitivity for example because of hypoxia is also difficult
to measure, especially since all sources of variation will
occur simultaneously and show interactions. Because of
thesevariations,tumourssmallerthan1cm
2 receiving peptide
radiotherapy with 277.5 MBq
177Lu-DOTA-octreotate
show regrowth in 25% of the animals, despite the TCP
of 100% based on the mean radiation dose. The fact that
tumours treated with an activity of 555 MBq do not show
regrowth shows that the variations in dose and other
parameters are less than 50% [8]. The large uncertainty in
the dose to these tumours, however, unfortunately pre-
vents the use of these data outside this empirical setting.
However, it was shown by Buffa and Nahum that the
typical (radio)biological heterogeneity in tumours has
more effect on tumour control than uncertainty in the
dose or dose distribution [30].
It is possible to use
111In as a surrogate for testing clinical
efficacy of a radiolabelled therapeutic pharmaceutical in
preclinical research, although the therapy should be designed
on an absorbed dose basis instead of the generally applied
activity scheme. Its reduced therapeutic efficacy in tumours
of intermediate size impedes easy interpretation, which is not
a factor in therapy experiments based on
177Lu. Dosimetry-
based tumour control studies involve determination of many
radiobiological parameters which are implicitly followed
when using the actual therapy radionuclide itself, and
enhance the science of the dose-effect by radionuclide
therapies beyond the empirical knowledge.
Open Access This article is distributed under the terms of the
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